The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety ...
ASP0113 is a DNA‐based vaccine for the prevention of CMV‐related mortality and end‐organ disease in transplant recipients. The efficacy, safety, and immunogenicity of ASP0113 was assessed in a phase 2, double‐blind, placebo‐controlled study in CMV‐seronegative kidney transplant recipients ...
ASP 0113 is a DNA ‐based vaccine for the prevention of CMV ‐related mortality and end‐organ disease in transplant recipients. The efficacy, safety, and immunogenicity of ASP 0113 was assessed in a phase 2, double‐blind, placebo‐controlled study in CMV ‐seronegative kidney transplant ...
CytomegalovirusDNA vaccineHematopoietic cell transplantationPhase 2 open-label trialClinicalTrials.gov Identifier: NCT01903928.Mori, TakehikoKeio UnivKanda, YoshinobuJichi Med UnivTakenaka, KatsutoOkamoto, ShinichiroKato, JunKanda, JunyaYoshimoto, GoichiGondo, HisashiDoi, SayakaInaba, MasakiKodera, Yoshihisa...
DNA vaccineimmunogenicitypharmacokinetics/pharmacodynamicsCytomegalovirus (CMV) infection causes significant morbidity and mortality in immunocompromised transplant patients. ASP0113, a first-in-class DNA vaccine containing plasmids encoding CMV phosphoprotein 65 and glycoprotein B (gB), was evaluated in a phase...